Sidoti Csr Has Positive Outlook of USNA FY2025 Earnings

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities researchers at Sidoti Csr raised their FY2025 EPS estimates for shares of USANA Health Sciences in a research report issued to clients and investors on Wednesday, April 23rd. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings of $2.61 per share for the year, up from their previous estimate of $2.59. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q4 2025 earnings at $0.68 EPS, Q2 2026 earnings at $0.79 EPS and Q4 2026 earnings at $0.93 EPS.

USNA has been the topic of several other reports. Sidoti cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. DA Davidson cut their target price on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Finally, StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th.

USANA Health Sciences Price Performance

USNA stock traded up $0.02 during trading on Friday, hitting $27.91. The stock had a trading volume of 69,362 shares, compared to its average volume of 123,175. USANA Health Sciences has a twelve month low of $23.10 and a twelve month high of $49.78. The stock has a market capitalization of $526.38 million, a P/E ratio of 9.86, a PEG ratio of 0.93 and a beta of 1.00. The company's 50-day moving average price is $27.69 and its two-hundred day moving average price is $33.08.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $249.54 million during the quarter, compared to analysts' expectations of $243.08 million. During the same period in the previous year, the business posted $0.86 EPS.

Institutional Trading of USANA Health Sciences

A number of institutional investors have recently bought and sold shares of USNA. Barclays PLC lifted its position in shares of USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company's stock valued at $1,052,000 after acquiring an additional 14,647 shares in the last quarter. Pzena Investment Management LLC lifted its position in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after buying an additional 37,466 shares in the last quarter. Principal Financial Group Inc. lifted its position in USANA Health Sciences by 2.8% during the fourth quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after buying an additional 1,480 shares in the last quarter. Rhumbline Advisers lifted its position in shares of USANA Health Sciences by 39.8% during the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock worth $1,773,000 after purchasing an additional 14,068 shares in the last quarter. Finally, Norges Bank acquired a new stake in USANA Health Sciences in the fourth quarter valued at $953,000. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other USANA Health Sciences news, CEO Jim Brown sold 5,000 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the sale, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joshua Foukas sold 5,732 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock valued at $500,285 over the last quarter. Company insiders own 0.63% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.